Back

Cell line resources for the study of neurofibromin: functions, phenotypes, and drug discovery/development

Liu, H.; Liu, J.; Li, C.; Luppi, E.; Rayat-Sanati, K.; Awad, E.; Westin, E.; Bedwell, D.; Hartman, M.; Leier, A.; Anastasaki, C.; Gutmann, D. H.; Kesterson, R.; Wallis, D.

2026-08-19 genetics
10.64898/2026.08.13.743550 bioRxiv
Show abstract

Our labs have been studying neurofibromin function and phenotype for over a decade with the intent of generating targeted therapeutics for Neurofibromatosis type 1 (NF1). In the process, we have generated numerous human cell lines containing variants within the NF1 gene. Herein, we present data characterizing these cell lines and make them publicly available for use by researchers both within and outside the NF1 community. We describe lines that contain both well-characterized patient-specific variants either at their endogenous locus or as exogenous cDNAs, as well as variants of uncertain significance (VUS), engineered as heterozygous, homozygous, and compound heterozygous variants. Methods to generate each line and subsequent validation steps are detailed including targeted sequencing, Western blot analysis for neurofibromin expression and ERK activation. The utility of each line is dependent on the variant of interest, the parental cell line, and the mechanism of action relevant to possible therapeutic targeting.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.